See how GLP-1 drugs reduce heart and kidney complications in MGUS and diabetes—explore the clinical evidence. Keep reading!

SGLT2 inhibitors, compared with GLP-1 RAs, were associated with lower risks for osteoarthritis and joint replacement surgery among patients with T2D.

The country’s Medicines and Healthcare products Regulatory Agency’s (MHRA) Yellow Card scheme, the UK’s official system for ...

Migraines are one of the world's most common neurological conditions, impacting nearly 15% of people globally. Despite this ...

A current weight-loss and diabetes drug has become a surprise candidate for migraine treatment, with a new pilot study ...

For people who constantly think about what they are going to eat meal to meal, their food noise goes down significantly’ ...

Novo Nordisk NVO has experienced remarkable growth in recent years, largely fueled by the commercial success of its ...

MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...

Improving access and affordability could be transformative for public health, given that about 88% of Americans are ...

VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

GLP-1RA use necessitated shifting priorities in nutrition and lifestyle modification among patients with obesity, according ...